InSitu Biologics, Inc.
StreetZero Signal 72
About InSitu Biologics, Inc.
InSitu Biologics is a near-clinical-stage Life Sciences company developing injectable sustained-release drug delivery technologies to extend therapeutic exposure to the target site. The company’s lead product candidate, INSB200™, is a ropivacaine-based sustained-release peripheral nerve block agent for post-operative pain management. Preclinical animal data have demonstrated sustained therapeutic release for up to five days while remaining within targeted safety parameters. It is based in Oakdale, MN and was founded in 2014.
LATEST FUNDINGPrivate Placement
$1.3M
Announced 2026-10-14
TOTAL RAISED$15.17M
IN THE NEWS
- 🔗 InSitu Biologics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 InSitu Biologics, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 InSitu Biologics Stock Price, Funding, Valuation, Revenue & Financial Statements
- 🔗 About | InSitu Biologics
- 🔗 InSitu Biologics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
EMPLOYEES10-50
FOUNDED2014
HQOakdale, MN, United States
Industry
Biotechnology
Tags
BiotechnologyDrug DeliveryPain ManagementSustained Release
Investors
Key highlights
- Lead candidate INSB200 provides up to five days of sustained ropivacaine release for post-operative pain.
- Total funding reached $15.17M across six rounds including a recent $1.25M convertible note.
- Attended the 47th Annual Regional and Acute Pain Medicine Meeting to present hydrogel-lipid-microparticle matrix data.
- Revenue estimated in the $10M-$25M range with focus on non-opiate pain relief for surgical procedures.
Ask StreetZero about InSitu Biologics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account